JP2021517128A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021517128A5 JP2021517128A5 JP2020546876A JP2020546876A JP2021517128A5 JP 2021517128 A5 JP2021517128 A5 JP 2021517128A5 JP 2020546876 A JP2020546876 A JP 2020546876A JP 2020546876 A JP2020546876 A JP 2020546876A JP 2021517128 A5 JP2021517128 A5 JP 2021517128A5
- Authority
- JP
- Japan
- Prior art keywords
- levodopa
- carbidopa
- secant
- top layer
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 34
- 229960004502 levodopa Drugs 0.000 claims 34
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 33
- 229960004205 carbidopa Drugs 0.000 claims 17
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 16
- 229940124597 therapeutic agent Drugs 0.000 claims 16
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 claims 9
- 229940052036 carbidopa / levodopa Drugs 0.000 claims 7
- 239000003937 drug carrier Substances 0.000 claims 6
- 208000018737 Parkinson disease Diseases 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 238000001990 intravenous administration Methods 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 4
- 229940015929 carbidopa 12.5 mg Drugs 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000004044 response Effects 0.000 claims 4
- 241000255925 Diptera Species 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 229940067290 levodopa 50 mg Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 238000011272 standard treatment Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022110134A JP2022133449A (ja) | 2018-03-29 | 2022-07-08 | レボドパ分割用量組成物および使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650012P | 2018-03-29 | 2018-03-29 | |
| US62/650,012 | 2018-03-29 | ||
| PCT/US2019/024464 WO2019191353A1 (en) | 2018-03-29 | 2019-03-28 | Levodopa fractionated dose composition and use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110134A Division JP2022133449A (ja) | 2018-03-29 | 2022-07-08 | レボドパ分割用量組成物および使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021517128A JP2021517128A (ja) | 2021-07-15 |
| JP2021517128A5 true JP2021517128A5 (enExample) | 2021-08-26 |
Family
ID=68060752
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546876A Pending JP2021517128A (ja) | 2018-03-29 | 2019-03-28 | レボドパ分割用量組成物および使用 |
| JP2022110134A Pending JP2022133449A (ja) | 2018-03-29 | 2022-07-08 | レボドパ分割用量組成物および使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110134A Pending JP2022133449A (ja) | 2018-03-29 | 2022-07-08 | レボドパ分割用量組成物および使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11033521B2 (enExample) |
| EP (1) | EP3773532A4 (enExample) |
| JP (2) | JP2021517128A (enExample) |
| CN (1) | CN111954523A (enExample) |
| BR (1) | BR112020017422A2 (enExample) |
| WO (1) | WO2019191353A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3773532A4 (en) * | 2018-03-29 | 2022-11-02 | Avion Pharmaceuticals, LLC | FRACTIONAL LEVODOPA DOSAGE AND USE |
| WO2022044045A1 (en) * | 2020-08-26 | 2022-03-03 | Rubicon Research Private Limited | Modified release formulations of levodopa |
| GB2644236A (en) * | 2024-09-24 | 2026-03-25 | Novumgen Ltd | Orodispersible tablet composition containing carbidopa and levodopa |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5061494A (en) * | 1990-06-14 | 1991-10-29 | The Upjohn Comany | Tri-scored drug tablet |
| CN1960712B (zh) * | 2004-05-21 | 2011-04-20 | 阿库-伯雷克技术公司 | 包含多个片段的刻痕药片 |
| US7838031B2 (en) | 2004-05-21 | 2010-11-23 | Lawrence Solomon | Method of administering a partial dose using a segmented pharmaceutical tablet |
| EP1755564B1 (en) * | 2004-05-21 | 2013-10-16 | Accu-Break Technologies, Inc. | Immediate release pharmaceutical tablets with height greater than width |
| US8506999B2 (en) | 2005-05-23 | 2013-08-13 | Accu-Break Technologies, Inc. | Pharmaceutical tablets comprising a plurality of segments |
| US20070275060A1 (en) * | 2005-08-05 | 2007-11-29 | Osmotica Costa Rica Sociedad Anonima | Extended release solid pharmaceutical composition containing carbidopa and levodopa |
| BRPI0520797B8 (pt) | 2005-11-18 | 2021-05-25 | Accu Break Tech Inc | forma de dosagem farmacêutica comprimida em bicamadas |
| KR20090057349A (ko) * | 2006-05-31 | 2009-06-05 | 솔베이 파머슈티컬스 게엠베하 | 레보도파／칼비도파의 ２４시간의 장기간 장내투여 |
| US20080131492A1 (en) * | 2006-06-23 | 2008-06-05 | Spherics, Inc. | Dosage forms for movement disorder treatment |
| CA2734972C (en) * | 2008-08-22 | 2017-03-28 | Wockhardt Research Centre | An extended release pharmaceutical composition of entacapone or salts thereof |
| PT3192500T (pt) * | 2009-05-19 | 2021-01-05 | Neuroderm Ltd | Composições para a administração contínua de inibidores da dopa decarboxilase |
| HUE056006T2 (hu) * | 2013-03-13 | 2022-01-28 | Neuroderm Ltd | Kombináció Parkinson-kór kezelésére |
| JP2016520540A (ja) * | 2013-03-28 | 2016-07-14 | オムニアクティブ ヘルス テクノロジーズ リミテッド | 脳内におけるカロテノイドの神経保護作用 |
| WO2016083863A1 (en) * | 2014-11-28 | 2016-06-02 | Bial - Portela & Ca, S.A. | Medicaments for slowing parkinson's disease |
| ES2895054T3 (es) * | 2016-08-18 | 2022-02-17 | Ilko Ilac Sanayi Ve Ticaret Anonim Sirketi | Fórmula de comprimido antiparkinson con perfil de disolución mejorado |
| EP3773532A4 (en) * | 2018-03-29 | 2022-11-02 | Avion Pharmaceuticals, LLC | FRACTIONAL LEVODOPA DOSAGE AND USE |
-
2019
- 2019-03-28 EP EP19775769.3A patent/EP3773532A4/en not_active Withdrawn
- 2019-03-28 BR BR112020017422-0A patent/BR112020017422A2/pt unknown
- 2019-03-28 CN CN201980023074.8A patent/CN111954523A/zh active Pending
- 2019-03-28 JP JP2020546876A patent/JP2021517128A/ja active Pending
- 2019-03-28 WO PCT/US2019/024464 patent/WO2019191353A1/en not_active Ceased
- 2019-12-18 US US16/719,203 patent/US11033521B2/en active Active
-
2021
- 2021-03-31 US US17/219,253 patent/US11439613B2/en active Active
-
2022
- 2022-07-08 JP JP2022110134A patent/JP2022133449A/ja active Pending
- 2022-08-26 US US17/896,808 patent/US11819485B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12226373B2 (en) | Treatment of fragile X syndrome with cannabidiol | |
| JP7442095B2 (ja) | ベータ－ヒドロキシブチレート及びブタンジオールのｓ－エナンチオマー並びにその使用方法 | |
| Schapira et al. | Study on the effects of tablet colour in the treatment of anxiety states | |
| ES2214729T3 (es) | Acido 9-cis-retinoico para enfermedades inmunes inducidas por celulas. | |
| Rigante et al. | The pharmacologic basis of treatment with colchicine in children with familial Mediterranean fever | |
| JP2021527092A5 (enExample) | ||
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| HUE035105T2 (en) | A composition comprising nicotine and opipramole and its use | |
| AU2310200A (en) | Pharmaceutical compositions | |
| US11826321B2 (en) | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions | |
| JP7429942B2 (ja) | テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミン（ａｎａｖｅｘ２－７３）のエナンチオマーならびにシグマ１レセプターにより調節されるアルツハイマー型および他の傷害の処置におけるその使用 | |
| JP2023543211A5 (enExample) | ||
| CN120659608A (zh) | 用于治疗癌症的tead抑制剂和kras g12d抑制剂组合 | |
| WO2024166059A1 (en) | Compositions comprising n,n-dimethyltryptamine, optionally in combination with n-acylethanolamines and uses thereof | |
| JP2016505050A5 (enExample) | ||
| ES2677474T3 (es) | Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiátricos | |
| US20250302773A1 (en) | Compositions comprising meai and n-acylethanolamines and uses thereof | |
| US6017946A (en) | Serotonin containing formulation for oral administration and method of use | |
| JP2024531799A5 (enExample) | ||
| EP0402208B1 (fr) | Association de vitamine A à dose physiologique et de différents principes actifs ayant une activité thérapeutique | |
| US11826326B2 (en) | Benzoic acid or a salt and derivative thereof for use in preventing or treating depression | |
| CA2990880A1 (en) | Thromboxane receptor antagonists in aerd/asthma | |
| CN108478581A (zh) | 防治运动病、梅尼埃病的药物及托伐普坦的医药用途 | |
| EP4665327A1 (en) | Compositions comprising 3,4-methylenedioxymethamphetamine, optionally in combination with n-acylethanolamines, and uses thereof | |
| JP2018177773A (ja) | 医薬 |